Company Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 20:28:33 06/03/2026 GMT			5-day change	1st Jan Change
102.71 ^CAD	-3.85%		-7.49%	-6.99%

02-13	Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT

Business description: Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Number of employees: 26

Sales by Activity: Bright Minds Biosciences Inc.

Fiscal Period: September	2021 (CAD)	2022 (CAD)	2023 (CAD)	2024 (CAD)	2025 (CAD)

See all business segments

Geographical breakdown of sales: Bright Minds Biosciences Inc.

Fiscal Period: September	2021 (CAD)	2022 (CAD)	2023 (CAD)	2024 (CAD)	2025 (CAD)

See all geographic segments

Executive Committee: Bright Minds Biosciences Inc.

Manager	Title	Age	Since
Ian McDonald CEO	Chief Executive Officer	38	04/06/2020
Ryan Cheung DFI	Director of Finance/CFO	47	28/05/2020
Stephen D. Collins CTO	Chief Tech/Sci/R&D Officer	-	06/01/2025
Alex Vasilkevich COO	Chief Operating Officer	-	31/05/2024
Jan Pedersen CTO	Chief Tech/Sci/R&D Officer	61	26/06/2022

See BRIGHT MINDS BIOSCIENCES INC. governance

Composition of the Board of Directors: Bright Minds Biosciences Inc.

Director	Title	Age	Since
Jeremy Fryzuk BRD	Director/Board Member	40	28/09/2020
Nils Bottler BRD	Director/Board Member	38	28/09/2020
Ian McDonald BRD	Director/Board Member	38	30/05/2019
Jan Pedersen BRD	Director/Board Member	61	31/03/2022
David Weiner BRD	Director/Board Member	61	16/02/2023

Composition of the Board of Directors

Shareholders: Bright Minds Biosciences Inc.

Name	Equities	%	Valuation
Janus Henderson Investors US LLC 11.88 %	1,155,995	11.88 %	90 M $
Janus Henderson Investors US LLC 11.88 %	1,155,995	11.88 %	90 M $
Cormorant Asset Management LP 10.88 %	1,059,331	10.88 %	82 M $
Cormorant Asset Management LP 10.88 %	1,059,331	10.88 %	82 M $
Ian McDonald 10.33 %	1,004,900	10.33 %	78 M $

List of BRIGHT MINDS BIOSCIENCES INC. shareholders

Company details: Bright Minds Biosciences Inc.

Bright Minds Biosciences, Inc.

400 North Aberdeen Street

60642, Chicago

http://www.brightmindsbio.com

address Bright Minds Biosciences Inc.(DRUG)

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BRIGHT MINDS BIOSCIENCES INC.	-3.85%	-7.49%	+95.64%	+2,467.75%	738M
LONZA GROUP AG	-2.02%	-5.97%	-10.82%	-8.73%	45.49B
BEONE MEDICINES AG	+2.79%	-5.01%	+21.88%	+30.07%	33.41B
CELLTRION, INC.	+0.47%	-10.90%	+20.11%	+49.32%	31.32B
IQVIA HOLDINGS INC.	-2.25%	-2.42%	-8.94%	-17.92%	29.29B
REVOLUTION MEDICINES, INC.	-1.24%	-3.55%	+150.96%	+300.16%	19.5B
ASCENDIS PHARMA A/S	+1.39%	+3.06%	+65.12%	+114.39%	14.77B
MEDPACE HOLDINGS, INC.	+0.26%	+4.17%	+41.40%	+136.11%	13.36B
EUROFINS SCIENTIFIC SE	-1.64%	-5.25%	+25.74%	+6.22%	13.21B
IONIS PHARMACEUTICALS, INC.	-1.49%	-8.76%	+118.99%	+107.63%	12.23B
Average	-0.76%	-4.28%	+52.01%	+318.50%	21.33B
Weighted average by Cap.	-0.43%	-4.61%	+32.49%	+66.61%